Tarsus Pharmaceuticals, Inc. Common Stock TARS
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $98.33 (+32.4% upside)
Key Stats
- Today's Range
- $74.20 – $77.61
- 50-Day Range
- $53.89 – $91.53
- 52-Week Range
- $48.20 – $91.53
- Volume
- 674K shs
- Average Volume
- 730K shs
- Market Cap
- $3.61 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 10.40
- Price / Sales
- 5.95
Short Interest
- Short Interest
- 0.31%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $606.33 million
- Net Income
- $-46,476,000
- Net Margin
- -7.67%
- Return on Equity
- -13.40%
- Debt-to-Equity
- 0.21
About Tarsus Pharmaceuticals, Inc. Common Stock
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Related Stocks
Compare head-to-head: TARS vs AMGN·TARS vs MRNA·TARS vs HALO·TARS vs RGEN
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.